Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482169 · ClinicalTrials.gov registry record · NA
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
A NA study, sponsored by Ochsner Health System.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT01482169 is a NA study that has completed, run by Ochsner Health System. The registered enrollment target is 48 participants.
The verdict
NCT01482169, a NA study, has completed, sponsored by Ochsner Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
Interventions
- DRUG FFR Measurement with IV Adenoscan® then with Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482169
The ClinicalTrials.gov registry entry for NCT01482169 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ochsner Health System, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FFR Measurement with IV Adenoscan® then with Regadenoson is the first listed.
NCT01482169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482169 about?
NCT01482169 is a clinical study titled "Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)". The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
What is the current status of trial NCT01482169?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2012-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01482169?
The interventions under investigation include: FFR Measurement with IV Adenoscan® then with Regadenoson (DRUG).
Who is sponsoring clinical trial NCT01482169?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.